Yuhan to go global with gastritis drug Revanex

Published: 2008-04-08 07:00:00

Updated: 2008-04-08 07:00:00

Yuhan Corporation has been most active with its homegrown gastric acid pump antagonist Revanex (revaprazan) in exploring a number of overseas markets, including 10 countries in South America.

Yuhan says it signed an exclusive licensing agreement with China's Shenzhen Zhijun Pharmaceutical Co.,...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK